Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. More is better: Combination therapies for myelodysplastic syndromes

    ... for MDS; lenalidomide , azacitidine , and decitabine . The role of these agents is to diminish the clinical impact of ...

    Research Article last updated 03/03/2015 - 2:41pm.

  2. Current therapy of myelodysplastic syndromes.

    ... therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last decade was a major ...

    Research Article last updated 09/03/2013 - 12:03pm.

  3. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

    ... that achieved response. Treatment of leukemia cells with decitabine resulted in a dose dependent up-regulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and ...

    Research Article last updated 12/17/2013 - 8:32am.

  4. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... lenalidomide ), and hypomethylating therapy [HMT ( decitabine and 5-azacytidine)]. All patients will eventually lose their ...

    Research Article last updated 01/20/2015 - 12:52pm.

  5. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

    ... for targeted therapies. Epigenetic therapy using decitabine , a DNA hypomethylating agent, is clinically effective for the ... at baseline did not correlate with clinical response to decitabine, we observed a significant correlation between reduced methylation ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Myelodysplastic syndromes: health care management considerations.

    ... approved for this indication-- azacitidine and decitabine --in terms of proven effectiveness, safe delivery, and survival ... discussion and study. The therapies azacitidine and decitabine may offer a good model for decision making to drive best treatment ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Recent developments in myelodysplastic syndromes

    ... (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to ...

    Research Article last updated 10/02/2014 - 10:30am.

  8. Update on the pharmacotherapy for myelodysplastic syndromes

    ... lenalidomide , azacitidine and decitabine . AREAS COVERED: This review summarizes the major ...

    Research Article last updated 08/21/2014 - 9:23am.

  9. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes

    ... Two demethylating agents, azacitidine and decitabine , are approved for treatment of MDS, though many patients do not ...

    Research Article last updated 08/04/2014 - 8:31am.

  10. Molecular pathogenesis of myelodysplastic syndromes

    ... options for MDS, including lenalidomide , decitabine , and 5-azacytidine, are targeted to improve transfusion ...

    Research Article last updated 05/22/2014 - 10:05am.